Express Pharma

Health Ministry proposes Good Storage and Distribution Practices under Drugs Rules, 1945

Proposed GSDP framework aims to strengthen regulatory oversight, accountability and quality assurance across the pharmaceutical supply chain

0 15

The Union Ministry of Health and Family Welfare has proposed the incorporation of Good Storage and Distribution Practices (GSDP) guidelines for pharmaceutical products into the Drugs Rules, 1945. The proposal aims to ensure that the quality, safety, efficacy and integrity of pharmaceutical products are maintained throughout the distribution chain, from the manufacturer or importer to the point of supply to the patient.

The proposed framework builds on the GSDP guidance developed by the Central Drugs Standard Control Organisation (CDSCO). The guidelines aim to ensure the quality and identity of pharmaceutical products at every stage of the distribution process, including procurement, purchasing, storage, distribution, transportation, documentation and record-keeping.

Maintaining appropriate storage and distribution conditions is essential to preserving the quality and integrity of pharmaceutical products beyond the manufacturing stage. The proposed GSDP framework seeks to address potential risks associated with their handling and movement across the supply chain, including deterioration, contamination, mix-ups, falsification, diversion and unauthorised distribution.

The incorporation of GSDP requirements into the Drugs Rules, 1945, is expected to strengthen the regulatory framework governing pharmaceutical distribution and support regulatory oversight, inspection and enforcement by the Central and State drug-control authorities. It will also promote documentation, record-keeping and traceability, while enhancing accountability among manufacturers, importers, wholesalers, distributors, stockists and other entities involved in the distribution process.

The proposed guidelines will further strengthen assurance that pharmaceutical products remain within specified quality and environmental conditions during storage and transportation. This is expected to reduce the risk of deterioration, contamination, mix-ups, falsification, diversion and unauthorised distribution, supporting the availability of pharmaceutical products of assured quality to patients and healthcare providers.

The proposed amendment represents a step towards strengthening India’s pharmaceutical quality-management system and ensuring that the quality established at the manufacturing stage is maintained throughout the supply chain until the product reaches the patient.

Stakeholders and members of the public have been invited to submit their objections and suggestions, if any, to the Under Secretary (Drugs Regulation), Ministry of Health and Family Welfare, Government of India, U-6, Work Hall, C Wing, First Floor, Kartavya Bhawan-1, New Delhi – 110001, or via email at drugsdiv-mohfw[at]gov[dot]in.

Leave A Reply

Your email address will not be published.